Desmethyl-Ofloxacin

Desmethyl-Ofloxacin

SCHEMBL6246239

CC1COc2c(N3CCNCC3)c(F)cc3c(=O)c(C(=O)O)cn1c23

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.81
ALDH1A1 P00352 6/20 0.81
HPGD P15428 5/20 0.81
HSD17B10 Q99714 3/20 0.81
ALB P02768 1/20 0.81
HRH3 Q9Y5N1 1/20 0.81
AADAT Q8N5Z0 2/20 0.79
TUBB4A P04350 1/20 0.79
POLB P06746 1/20 0.79
TUBB P07437 1/20 0.79
TUBA3C P0DPH7 1/20 0.79
TUBA1B P68363 1/20 0.79
TUBA4A P68366 1/20 0.79
TUBB4B P68371 1/20 0.79
TUBB3 Q13509 1/20 0.79
TUBB2A Q13885 1/20 0.79
TUBB8 Q3ZCM7 1/20 0.79
TUBA3E Q6PEY2 1/20 0.79
TUBA1A Q71U36 1/20 0.79
SLC47A1 Q96FL8 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Desmethyl-Ofloxacin SCHEMBL30542144 1.00 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10ALB
N-Desmethyl Levofloxacin SCHEMBL30306092 1.00 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10ALB
N-Desmethyl Levofloxacin SCHEMBL5021672 1.00 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10ALB
N-Desmethyl Levofloxacin SCHEMBL20577525 0.99 KDM4E (0.79) KDM4EALDH1A1HPGDHSD17B10ALB
Desmethyl-Ofloxacin SCHEMBL6247374 0.99 KDM4E (0.79) KDM4EALDH1A1HPGDHSD17B10ALB
Hydrochloric Acid SCHEMBL11075292 0.95 KDM4E (0.74) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL26197440 0.91 KDM4E (0.85) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL11198681 0.91 KDM4E (0.85) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL4545209 0.90 KDM4E (0.84) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL10931342 0.90 KDM4E (0.74) KDM4EALDH1A1HPGDHSD17B10ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115586264-B Non-targeted screening method for veterinary drugs and metabolites thereof in milk 中国科学院大连化学物理研究所 2024-11-12 CN disclosed
CN-116831986-A Levofloxacin sodium chloride injection and preparation method thereof 成都医路康医学技术服务有限公司 2023-10-03 CN disclosed
WO-2017133517-A1 PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF 四川海思科制药有限公司 2017-08-10 WO disclosed
US-20140199391-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND API GENESIS, LLC (US) 2014-07-17 US disclosed
US-20140073631-A1 ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS VYMED CORPORATION (US) 2014-03-13 US disclosed
US-20140073631-A1 ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS VYMED CORPORATION (US) 2014-03-13 US disclosed
US-20140073631-A1 ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS VYMED CORPORATION (US) 2014-03-13 US disclosed
US-6967205-B1 Compounds with antibacterial and antiparasitic properties NEW PHARMA RESEARCH SWEDEN AB (SE) 2005-11-22 US disclosed
EP-1406619-A4 ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES SHETTY B VITHAL (US) 2005-02-02 EP disclosed
US-20040132993-A1 Antiviral and antimicrobial guanidine or biguanidine derivatives SHETTY B VITHAL (US) 2004-07-08 US disclosed
US-5637580-A ANTIBIOTICS THE PROCTER & GAMBLE COMPANY (US) 1997-06-10 US disclosed
US-5491139-A Antimicrobial quinolonyl lactams THE PROCTER & GAMBLE COMPANY (US) 1996-02-13 US disclosed
US-5387748-A Antimicrobial dithiocarbamoyl quinolones PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1995-02-07 US disclosed
EP-0489733-A1 ANTIBACTERIAL PYRIDO(1,2,3-DE)-1,4-BENZOXAZINONE AGENTS THE UPJOHN COMPANY (US) 1992-06-17 EP disclosed
WO-1990012799-A1 ANTIBACTERIAL PYRIDO(1,2,3-DE)-1,4-BENZOXAZINONE AGENTS THE UPJOHN COMPANY (US) 1990-11-01 WO disclosed
EP-0366193-A2 Novel antimicrobial quinolonyl lactams Norwich Eaton Pharmaceuticals, Inc. (US) 1990-05-02 EP disclosed
EP-0366189-A2 Novel antimicrobial lactam-quinolones Norwich Eaton Pharmaceuticals, Inc. (US) 1990-05-02 EP disclosed
EP-0047005-B1 BENZOXAZINE DERIVATIVES DAIICHI SEIYAKU CO., LTD. (JP) 1984-11-14 EP disclosed
US-4382892-A Benzoxazine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1983-05-10 US disclosed
EP-0047005-A1 Benzoxazine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1982-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140199391-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND ABCG2, CYP2F1, LSS KDM4E 2079/4885ALDH1A1 1920/4885HPGD 244/4885
US-20140073631-A1 ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS GDA, GMPS, GANC KDM4E 2392/4885ALDH1A1 2165/4885HPGD 968/4885
US-20040132993-A1 Antiviral and antimicrobial guanidine or biguanidine derivatives GMPS, GDA, GANC KDM4E 2140/4885ALDH1A1 2918/4885HPGD 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.